Check a POLE/POLD cancer drug for non–MSI-high tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old and have an advanced solid tumor confirmed by biopsy or cell testing
- Your tumor is POLE or POLD mutated (not just a “synonymous” change) and it is not MSI-H or dMMR
- Your cancer has measurable disease on scans, and your health status is good enough (ECOG 0–1)
- You must be willing to do tumor biopsies and blood tests before treatment and at check-in visits
- You must NOT have had treatment with PD-1/PD-L1/CTLA-4 or other immune checkpoint drugs in the past 4 weeks
- You are able to meet key blood/liver/organ lab levels (and for people who can become pregnant, you agree to pregnancy prevention)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with higher-risk, locally advanced rectal cancer. It is meant for cancers that are mismatch-repair “MSS/pMMR,” and it checks safety plus effectiveness as a first treatment.
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.